AX-2026-042420
Glucagon · 5 mg declared · Hunan Aslsen Technology Co., Ltd. · lot HOMO-2602-V3961
- Report ID
- AX-2026-042420
- Compound
- Glucagon
- Compound class
- Incretin analogues and co-agonists
- Supplier
- Homopeptide — Hunan Aslsen Technology Co., Ltd.
- Batch / lot
- HOMO-2602-V3961
- Declared label claim
- 5mg
- Laboratory
- Medutest
- Assay date
- 10 Apr 2026
- Submitted
- 25 Apr 2026
- Quarter
- 2026-Q2
- Submitter
- g.halvorsen
- Sample provenance
- Buyer-sourced
Results
Measured against the index acceptance specification for the incretin analogues and co-agonists class. A specification is a decision the index made; a result is a measurement. See where each threshold came from.
| Parameter | Method | Result | Unit | Index spec | |
|---|---|---|---|---|---|
| Purity | RP-HPLC, 25 min gradient, 214 nm | 98.88 | % area | ≥ 98.0 | PASS |
| Total impurities | RP-HPLC, sum of reported peaks | 1.12 | % area | ≤ 2.0 | PASS |
| Largest single impurity | RP-HPLC — Met27 sulfoxide (+16 Da) | 0.78 | % area | ≤ 1.00 | PASS |
| Identity — theoretical monoisotopic mass | calculated from molecular formula | 3480.6194 | Da | — | NOT TESTED |
| Identity — observed monoisotopic mass | LC-MS, unit resolution (single quadrupole) | 3480.6375 | Da | — | NOT TESTED |
| Mass accuracy | observed vs theoretical | +5.2 | ppm | ± 15 | PASS |
| Total peptide content | by difference from the gravimetric mass balance | 88.98 | %w/w | — | NOT TESTED |
| Target-compound content | total peptide content × purity | 87.98 | %w/w | — | NOT TESTED |
| Gross fill (as weighed) | five-place balance, under nitrogen | 5.68 | mg | 5 mg declared | NOT TESTED |
| Recovered target peptide | gross fill × target content | 4.997 | mg | 5 mg claim | NOT TESTED |
| Recovery against label claim | recovered ÷ claim | 99.9 | % | 90.0 – 110.0 | PASS |
| Water content | Karl Fischer, coulometric, duplicate | 6.60 | % | ≤ 8.0 | PASS |
| Counter-ion (acetate) | anion-exchange ion chromatography | 4.22 | % | ≤ 12.0 | PASS |
| Residual solvent + inorganic residue | estimated — see /methods/residual-solvents-q3c/ | 0.20 | % | — | NOT TESTED |
| Endotoxin | not ordered on this submission | not determined | — | ≤ 5.0 | NOT TESTED |
| Sterility | not ordered on this submission | not determined | — | no growth | NOT TESTED |
| Appearance | visual, diffuse light, black and white background | White lyophilised cake, intact | — | white to off-white intact cake | PASS |
| Reconstitution clarity | reconstituted per submitter procedure | Visible particulates, did not clear | — | clear, no visible particulates | FAIL |
| pH (reconstituted, 1 mg/mL) | potentiometric, two-point calibration | 5.28 | — | 2.5 – 8.0 | PASS |
| Retention time (observed) | RP-HPLC, 25 min gradient | 11.49 | min | 11.52 ± 0.35 (normalised) | PASS |
| Peak asymmetry (10 % height) | Ph. Eur. 2.2.46 | 1.13 | — | 0.80 – 1.50 | PASS |
| Plate count, main peak | N = 5.54 (t/w½)² | 84,509 | — | ≥ 20,000 | PASS |
| Resolution to nearest impurity | vs deamidated Asn28 (+1 Da) | 1.85 | — | no index criterion | REPORTED |
Chromatogram and peak integration
The figure is drawn from the table. It is not an independent illustration — if a number in the table changed, the trace would change with it.
| # | Peak | RT | Area (µV·s) | % area | Δ mass (Da) |
|---|---|---|---|---|---|
| 1 | Glucagon — main peak | 11.49 | 4,805,875 | 98.88 | — |
| 2 | Met27 sulfoxide (+16 Da) | 10.83 | 37,910 | 0.78 | +15.995 |
| 3 | des-His1 (−137 Da) | 10.71 | 11,179 | 0.23 | -137.059 |
| 4 | deamidated Asn28 (+1 Da) | 11.19 | 2,916 | 0.06 | +0.984 |
| 5 | glucagon fibril-derived aggregate | 13.66 | 2,430 | 0.05 | 0.000 |
| Closure check — purity + Σ impurities | 100.00 | CLOSES | |||
Reporting threshold 0.05 % area. Peaks below it are not reported and are therefore excluded from the total, which overstates purity by their sum — see peak integration.
Mass spectrum and identity
Theoretical monoisotopic mass 3480.6194 Da, computed from C153H225N43O49S. All ppm figures on this site are against monoisotopic values — see why that matters.
| Charge | Theoretical m/z | Observed m/z | Δ m/z | Rel. abundance (%) |
|---|---|---|---|---|
| 5+ | 697.1312 | 697.1348 | 0.0036 | 7.9 |
| 4+ | 871.1621 | 871.1667 | 0.0046 | 52.7 |
| 3+ | 1161.2137 | 1161.2198 | 0.0061 | 100.0 |
| 2+ | 1741.3170 | 1741.3260 | 0.0090 | 52.6 |
Gravimetric mass balance
Water, counter-ion, residual and total peptide content are exhaustive and mutually exclusive categories. They must account for 100 % of the cake mass. The index closes this to within 0.02 pp and the build asserts it.
| Component | Determination | %w/w of cake |
|---|---|---|
| Water | Karl Fischer | 6.60 |
| Counter-ion (acetate) | ion chromatography | 4.22 |
| Residual solvent + inorganic residue | estimated | 0.20 |
| Total peptide content | by difference | 88.98 |
| Total | 100.00 CLOSES | |
Supplier certificate, as declared
The supplier's own figures for this lot, beside the independent measurement. Divergence is assessed against the batch median, not against this single report — see rule AX-R05.
| Figure | Supplier COA | This report | Index note |
|---|---|---|---|
| Purity (% area) | 99.31 | 98.88 | divergence +0.09 pp vs batch median |
| Total impurities (% area) | 0.69 | 1.12 | |
| Largest single impurity (% area) | 0.39 | 0.78 | |
| Water (%) | 5.8 | 6.60 | |
| Counter-ion (%) | not stated | 4.22 | |
| Peptide content (%w/w) | not stated | 88.98 | |
| Endotoxin (EU/mg) | 0.40 | not determined | |
| Method stated on certificate | NO | — | no method section — the result cannot be reconciled against any other |
Provenance and caveats
Where a sample came from changes the weight of the evidence. The index treats it as a first-class field.
- Sample provenance
- Buyer-sourced
- Evidentiary weight
- Strongest available evidence in this index.
- Chain of custody
- Retail purchase → submitter (ambient, 24 d) → laboratory (hand-carried, 9 d) → assay.
- Assay date
- 10 Apr 2026
- Submitted to the index
- 25 Apr 2026
- Laboratory
- Medutest, Ljubljana, Slovenia
- Method basis
- 25 min gradient · unit-resolution MS
- Verification status
- IDENTITY CONSISTENT
Annotations
No annotations on this record. Annotations are short signed technical comments from index contributors; see how to contribute.
Related records
Same batch — lot HOMO-2602-V3961 n=12
| Report | Lot | Lab | Quarter | Purity % | Water % | Recovery % | Provenance | Flags | Result |
|---|---|---|---|---|---|---|---|---|---|
| AX-2026-042411 | HOMO-2602-V3961 | Janoshik | 2026-Q2 | 99.00 | 6.22 | 98.9 | Buyer-sourced | 0 | PASS |
| AX-2026-042412 | HOMO-2602-V3961 | Janoshik | 2026-Q2 | 99.32 | 6.35 | 102.2 | Buyer-sourced | 0 | PASS |
| AX-2026-042413 | HOMO-2602-V3961 | Janoshik | 2026-Q2 | 99.25 | 6.65 | — | Buyer-sourced | 0 | PASS |
| AX-2026-042414 | HOMO-2602-V3961 | PeptideMeter | 2026-Q2 | 98.87 | 6.63 | — | Buyer-sourced | 0 | PASS |
| AX-2026-042415 | HOMO-2602-V3961 | VendorInvestigate | 2026-Q2 | 99.59 | 6.65 | 97.4 | Buyer-sourced | 0 | PASS |
| AX-2026-042416 | HOMO-2602-V3961 | Janoshik | 2026-Q2 | 99.60 | 6.15 | — | Buyer-sourced | 0 | PASS |
| AX-2026-042417 | HOMO-2602-V3961 | VendorInvestigate | 2026-Q2 | 99.09 | 7.02 | 99.8 | Buyer-sourced | 0 | PASS |
| AX-2026-042418 | HOMO-2602-V3961 | Medutest | 2026-Q2 | 99.20 | 6.31 | 97.8 | Buyer-sourced | 0 | PASS |
| AX-2026-042419 | HOMO-2602-V3961 | Janoshik | 2026-Q2 | 99.21 | 6.84 | — | Buyer-sourced | 0 | PASS |
| AX-2026-042421 | HOMO-2602-V3961 | PeptideMeter | 2026-Q2 | 99.38 | 6.63 | 95.7 | Buyer-sourced | 0 | PASS |
| AX-2026-042422 | HOMO-2602-V3961 | Janoshik | 2026-Q2 | 99.23 | 6.89 | — | Buyer-sourced | 0 | PASS |
Cross-sections
| Report | Supplier | Lot | Lab | Quarter | Purity % | Water % | Recovery % | Provenance | Flags | Result |
|---|---|---|---|---|---|---|---|---|---|---|
| AX-2026-042421 | Homopeptide | HOMO-2602-V3961 | PeptideMeter | 2026-Q2 | 99.38 | 6.63 | 95.7 | Buyer-sourced | 0 | PASS |
| AX-2026-042411 | Homopeptide | HOMO-2602-V3961 | Janoshik | 2026-Q2 | 99.00 | 6.22 | 98.9 | Buyer-sourced | 0 | PASS |
| AX-2026-042413 | Homopeptide | HOMO-2602-V3961 | Janoshik | 2026-Q2 | 99.25 | 6.65 | — | Buyer-sourced | 0 | PASS |
| AX-2026-042416 | Homopeptide | HOMO-2602-V3961 | Janoshik | 2026-Q2 | 99.60 | 6.15 | — | Buyer-sourced | 0 | PASS |
| AX-2026-042419 | Homopeptide | HOMO-2602-V3961 | Janoshik | 2026-Q2 | 99.21 | 6.84 | — | Buyer-sourced | 0 | PASS |
| AX-2026-042418 | Homopeptide | HOMO-2602-V3961 | Medutest | 2026-Q2 | 99.20 | 6.31 | 97.8 | Buyer-sourced | 0 | PASS |
| AX-2026-042412 | Homopeptide | HOMO-2602-V3961 | Janoshik | 2026-Q2 | 99.32 | 6.35 | 102.2 | Buyer-sourced | 0 | PASS |
| AX-2026-042422 | Homopeptide | HOMO-2602-V3961 | Janoshik | 2026-Q2 | 99.23 | 6.89 | — | Buyer-sourced | 0 | PASS |
| Report | Compound | Lot | Lab | Quarter | Purity % | Water % | Recovery % | Provenance | Flags | Result |
|---|---|---|---|---|---|---|---|---|---|---|
| AX-2026-042437 | Retatrutide | HOMO-2605-V4718 | Nordanalyt | 2026-Q3 | 98.68 | 3.67 | 102.8 | Buyer-sourced | 0 | PASS |
| AX-2026-042424 | Semaglutide | HOMO-2604-X3806 | PeptideMeter | 2026-Q3 | 98.85 | 4.87 | 92.0 | Buyer-sourced | 0 | PASS |
| AX-2026-042503 | IGF-1 LR3 | HOMO-2607-P5131 | Janoshik | 2026-Q3 | 99.36 | 5.99 | — | Buyer-sourced | 0 | PASS |
| AX-2026-042492 | SS-31 (Elamipretide) | HOMO-2604-D5484 | Medutest | 2026-Q3 | 99.93 | 2.40 | — | Buyer-sourced | 0 | PASS |
| AX-2026-042491 | SS-31 (Elamipretide) | HOMO-2604-D5484 | Kestrel | 2026-Q3 | 99.93 | 3.24 | — | Supplier-supplied | 0 | PASS |
| AX-2026-042473 | LL-37 | HOMO-2602-G5165 | Janoshik | 2026-Q3 | 99.01 | 5.00 | — | Buyer-sourced | 0 | PASS |
| AX-2026-042441 | Retatrutide | HOMO-2605-V4718 | Medutest | 2026-Q3 | 98.93 | 4.22 | — | Buyer-sourced | 0 | PASS |
| AX-2026-042474 | LL-37 | HOMO-2602-G5165 | Janoshik | 2026-Q3 | 99.18 | 5.44 | — | Buyer-sourced | 0 | PASS |